Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated development and manufacturing capabilities. With our platform we develop and manufacture specialized, terminally-differentiated human cells from our pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury, or administered as a means of helping the body mount an effective immune response to cancer.
Lineage is developing three cell therapy programs (see our Pipeline):
- OpRegen® – a cell replacement therapy comprised of retinal pigment epithelium cells and currently being tested in a Phase 1/2a multicenter clinical trial for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. The development of OpRegen has been partially supported by more than $14 million of grants from the Israel Innovation Authority. OpRegen has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA).
- OPC1 – a cell replacement therapy comprised of oligodendrocyte progenitor cells and currently being tested in a Phase 1/2a multicenter clinical trial for the treatment of acute spinal cord injuries (SCI). The development of OPC1 has been partially funded by a $14.3 million grant from the California Institute for Regenerative Medicine or CIRM. OPC1 has received Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of acute SCI and has been granted Orphan Drug Designation by the FDA.
- VAC2 – an allogeneic (non-patient-specific or “off-the-shelf”) cancer immunotherapy comprised of mature, antigen-presenting dendritic cells and currently being tested in a Phase I clinical trial in patients with non-small cell lung cancer (NSCLC). VAC2 has been partially supported by Cancer Research UK, the world’s largest independent cancer research charity, and which is responsible for costs and conduct of the clinical trial.
Lineage’s lead cell delivery clinical program is Renevia®, a medical device that was developed as a replacement for whole adipose tissue in cell assisted lipotransfer (CAL) procedures.
In September 2019, Renevia received a Class III classification with an intended use in adults as a resorbable matrix for the delivery of autologous adipose tissue preparations to restore and/or augment facial volume after subcutaneous fat volume loss for the treatment of facial lipoatrophy. The CE Mark provides Lineage, or its authorized agent, the authority to market and distribute Renevia throughout the European Union (EU) and in other countries that recognize the CE Mark.
Lineage has engaged Sercader Ltd., a European based, life sciences advisory firm, to identify an external commercialization partner with the capabilities and infrastructure to launch and further develop Renevia in the European market (Read more about Lineage’s Cell/Drug Delivery Technology).
We also have investments in public companies AgeX, Inc. and OncoCyte Corporation.
We are a publicly traded company listed on the NYSE American and TASE under the symbol LCTX.